ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD20
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD20
41
trial(s) found.
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
2024-517131-52-00--BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (
CaDAnCe-302
)
BTK PROTAC degrader
Bcl2 inhibitor
PI3K delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - ICON Cancer Centre Toowoomba
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06806033
Haem
Phase 2
Recruiting
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
GO45434
)
antimetabolite
bispecific T-cell engager,CD20-targeting
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06717347
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) (
MK-2140-010--2140-010
)
anti-ROR1 antibody-drug conjugate
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06634589
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
2024-516234-35-00--BGB-16673-104
)
BTK PROTAC degrader
+ anti-CD20 monoclonal antibody
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06564038
Haem
Phase 1
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
+ anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06542250
Haem
Phase 1
Recruiting
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (
TITANium
)
bispecific T-cell engager,CD20-targeting
B-cell malignancy
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06539338
Haem
Phase 1
Recruiting
A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older with Refractory/Relapsing B-cell Malignancies (
INVISE
)
allogeneic CAR-T/NK-cell therapy,CD20-targeting
Leukaemia
Lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06508658
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
EPCORE-DLBCL-4
)
anti-CD20 monoclonal antibody
antimetabolite
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
platinum-based antineoplastic agent
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
2024-512147-23-00--M24-287
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06287398
Haem
Phase 2
Recruiting
A Trial to Assess the Safety and Efficacy of Epcoritamab-containing Combination Salvage Therapy Followed by Autologous Stem Cell Transplantation and Epcoritamab Consolidation in Patients With Relapsed Large B-cell Lymphoma (
NHL38
)
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
NCT06230224
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (
OLYMPIA-4
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06047080
Haem
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (
GO44145
)
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
anti-CD79b antibody-drug conjugate
bispecific T-cell engager,CD20-targeting
glucocorticoid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05991388
Paed
Phase 2
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ anti-CD20 monoclonal antibody
Non-Hodgkin's lymphoma
NCT05947851
Haem
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
MK-1026-010--1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05896163
Haem
Phase 1
Recruiting
A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION (
MAPtivate-6
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05784441
Haem
Phase 1
Recruiting
A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (
90009530LYM1001--90009530LYM1001
)
autologous CAR-T-cell therapy,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05421663
Haem
Phase 1
Recruiting
A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma (
90014496LYM1001--90014496LYM1001
)
autologous CAR-T cell therapy,bispecific CD19/CD20-targeting
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05279300
Advanced
Phase 1
Recruiting
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas (
CS5001-101
)
anti-ROR1 antibody-drug conjugate
+ anti-CD20 monoclonal antibody
Lymphoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide (TERMINATED)
NCT05139017
Haem
Phase 2
Recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (
VLS-101--2140-003
)
anti-ROR1 antibody-drug conjugate
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05091424
Haem
Phase 1
Recruiting
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (
BO43243
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04989803
Haem
Phase 1
Recruiting
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (
2020-000562-41--KT-US-499-0150
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NCT04895436
Haem
Phase 2
Recruiting
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia (
ReVenG
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
+ anti-CD20 monoclonal antibody
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04623541
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04442022
Haem
Phase 2
Recruiting
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) (
2020-000605-84--XPORT-DLBCL-030
)
XPO1 inhibitor
anti-CD20 monoclonal antibody
antimetabolite
glucocorticoid
Diffuse large B-cell lymphoma
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, =80 Years, or Frail =75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03888105
Haem
Phase 2
Recruiting
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (
ELM-2
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
NCT03816254
Advanced
Phase 1
A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers (
U1111-1224-8251--CC-95251-ST-001
)
anti-CD20 monoclonal antibody
anti-EGFR monoclonal antibody
anti-SIRPa monoclonal antibody
Cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
ACTRN12625000732482
Haem
Phase 2
Not yet recruiting
CLL12 - An ALLG phase II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (
AETHER-trial
)
Bcl2 inhibitor
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
ACTRN12625000673448
Haem
Phase 2
Not yet recruiting
Detection of Ultra-High Risk Large B-Cell Lymphoma for Early Delivery of Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY study (
ALLG-NHL34-DA
)
autologous CAR-T-cell therapy,CD19-targeting
+ anti-CD20 monoclonal antibody
Diffuse large B-cell lymphoma
ACTRN12625000387426
Haem
Phase 2
Not yet recruiting
CLL11 - An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (
MOONSHOT
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
ACTRN12624001142527
Haem
Phase 4
Not yet recruiting
Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (
nil
)
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Follicular lymphoma
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12623000640606
Haem
Phase 2
Recruiting
CLL08 - A phase 2 study of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory CLL patients with disease progression following VenR as their last line of therapy
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
ACTRN12623000620628
Haem
Phase 2
Recruiting
NHL38 Epco-Sandwich: A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with relapsed large B-cell lymphoma.
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
+ anti-CD20 monoclonal antibody
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (35)
Not yet recruiting (5)
Recruitment Country and State
VIC (30)
NSW (20)
QLD (20)
WA (16)
NZ (8)
SA (8)
TAS (4)
ACT (3)
NT (1)
Phase
Phase 1 (13)
Phase 1 / Phase 2 (1)
Phase 2 (14)
Phase 3 (12)
Phase 4 (1)
Trial Type
Haem (35)
Paed (4)
Advanced (2)
Cancer Therapy Class
CD20
100%
Bcl2
29%
BTK
17%
CD19
15%
cereblon
15%
ROR1
7%
CD79b
7%
IL-6
7%
PI3K delta
2%
XPO1
2%
EGFR
2%
SIRPa
2%
PD-1
2%
PD-1/PD-L1
2%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
3004 - Melbourne, Southbank - Alfred Health (7)
6000 - Perth - Royal Perth Hospital (7)
3168 - Clayton - Monash Medical Centre (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
3066 - Epping - Northern Hospital (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
2139 - Concord - Concord Repatriation General Hospital (4)
3002 - East Melbourne - Epworth Freemasons (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
7000 - Hobart - Royal Hobart Hospital (4)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (4)
2217 - Kogarah - St George Hospital (3)
2605 - Garran - The Canberra Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (3)
5042 - Bedford Park - Flinders Medical Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2480 - Lismore - Lismore Base Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
6168 - Cooloongup - Rockingham Hospital (1)
4350 - Toowoomba - ICON Cancer Centre Toowoomba (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2500 - Wollongong - Wollongong Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
Mature B-cell malignancy
B-cell lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Leukaemia
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Mantle cell lymphoma
Solid tumour
Follicular lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy